Update on Rivaroxaban UK Proceedings: A Roller Coaster Ride for Generic Companies
In the United Kingdom, multiple generic competitors initiated invalidity lawsuits seeking revocation of Bayer’s key dosing patent protecting Xarelto 10, […]
May 2, 2024